Clinical trial
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children…
NCT00039481 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00039481 |
|---|---|
| Title | Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors |
| Official title | A Phase I Trial Of G3139 (BCL-2 Antisense, NSC# 683428, IND# 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, filgrastim, laboratory biomarker analysis, pharmacological study |
| Enrollment | 15 |
| Start date | Nov 1, 2002 |
| Primary completion | Oct 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: